ESR1 and breast carcinoma: Although the treatment of breast cancer has been greatly advanced in the past decades due to the discovery of specific predictive, diagnostic and prognostic biomarkers such as ERalpha and human epidermal growth factor receptor 2 (HER2), about one-third of metastatic ERalpha-positive tumors fail to respond to endocrine therapy [10–13].